Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis

BACKGROUND: In 2020, atezolizumab-bevacizumab became the new standard of care (SOC) for first-line unresectable hepatocellular carcinoma (HCC) patients, following a decade where sorafenib was the preferred first-line treatment. In the last few years, a number of novel systemic treatments with non-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogel, Arndt, Finn, Richard S., Blanchet Zumofen, Marie-Hélène, Heuser, Carolina, Alvarez, Javier Sanchez, Leibfried, Michael, Mitchell, Catherine R., Batson, Sarah, Redhead, Gabrielle, Gaillard, Vincent E., Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697759/
http://dx.doi.org/10.1159/000533166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10697759/
http://dx.doi.org/10.1159/000533166

Ejemplares similares